<DOC>
	<DOCNO>NCT03027960</DOCNO>
	<brief_summary>The investigator propose small pilot proof concept study prove existence , also probe mechanism underlie cardio-renal effect empagliflozin patient heart failure . The investigator propose 50 patient randomize , double-blind , placebo-controlled crossover study patient stable HF , type II diabetes eGFR &gt; 45ml/min/1.73 m2 chronically receive loop diuretic .</brief_summary>
	<brief_title>Empagliflozin Heart Failure : Diuretic Cardio-Renal Effects</brief_title>
	<detailed_description>Study Objectives 1 . Study acute/short term effect cardio-renal mechanism sodium-glucose cotransporter 2 ( SGLT2 ) inhibition patient heart failure . 2 . Determine effect chronic combine SLLGT2 loop diuretic exposure patient heart failure . Primary Outcomes 1 . Aim 1 ( Acute ) : Determine acute SGLT2 inhibition improve natriuretic effect loop diuretic compare placebo . 2 . Aim 2 ( Chronic ) : Determine effect 14 day SGLT2 inhibition blood volume .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Stable HF define : No hospitalization &gt; 60 day Stable HF medication &gt; =2 week , stable diuretic 4 week Opinion HF cardiologist patient optimal volume status Chronic daily oral loop diuretic dose &gt; =20mg furosemide equivalent Diagnosis type II diabetes Patient monitor blood glucose regularly home eGFR &gt; =45 mL/min/1.73 m2 &gt; =18 year old Active titration chronic HF medication expect study period Use nonloop diuretic , aside aldosterone antagonist ( &lt; =25mg spironolactone &lt; =50mg eplerenone ) Critical stenotic valvular disease , complex congenital heart disease , prior heart transplant History diabetic ketoacidosis , `` brittle '' diabetes , and/or frequent hypoglycemia severe hypoglycemic episode require emergent intervention ( ER visit EMS response , glucagon administration force oral carbs ) last 6 month History bladder dysfunction , incontinence , pyelonephritis , urosepsis , frequent urinary tract infection Anemia ( define hemoglobin &lt; 8g/dL ) Pregnancy breastfeed History serious hypersensitivity Participation another trial investigational drug within 30 day prior informed consent Use another SGLT2 inhibitor Appears unlikely , unable participate require study procedure , assess study PI research RN ( ex : clinicallysignificant psychiatric , addictive , neurological disease ) Inability give write informed consent follow study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>cardio-renal</keyword>
</DOC>